Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hVEGF-A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| hVEGF-A | GENETIC | - |
Inclusion Criteria: * Have a clinical diagnosis of Diabetes Mellitus Type I or II for at least 12 months prior to the study. * Have received a diagnosis of mild to moderate sensori-motor diabetic neuropathy from a neurologist (a doctor who specializes in disorders of the nervous system) or endocrin...
hVEGF-A is an investigational gene therapy developed by Sangamo Therapeutics, Inc. for diabetic neuropathy. It delivers the human vascular endothelial growth factor A gene and was studied in a single Phase 1 clinical trial that has been completed. It is not an approved medicine.
hVEGF-A was developed as a gene therapy candidate for diabetic neuropathy, a neurologic complication of diabetes. Sangamo Therapeutics evaluated it in a Phase 1 study enrolling 12 participants with the condition in the United States. The program remains investigational, and no approved use in diabetic neuropathy exists.
hVEGF-A is developed by Sangamo Therapeutics, Inc., which trades under the ticker SGMOQ. The company sponsored the Phase 1 clinical trial of the gene therapy candidate in diabetic neuropathy. Sangamo is the developer associated with this asset.
hVEGF-A is in Phase 1 development. Its only recorded clinical trial, NCT00110500, was a Phase 1 study in diabetic neuropathy that has been completed. The candidate is investigational and has not been approved by the FDA for any indication.
hVEGF-A has been studied in one clinical trial, NCT00110500, titled Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy. The Phase 1 study was completed, enrolled 12 participants, was uncontrolled, and was conducted in the United States in adults aged 18 years and older.